Pharmacist-led Transitions of Care in the Outpatient Oncology Infusion Center for Patients With Solid Tumor

Overview

This trial studies how well pharmacist-led transitions of care works in the outpatient oncology infusion center for patients with solid tumor. Having a pharmacist in the outpatient oncology infusion center may help to identify and correct medical related problems and improve overall patient and staff satisfaction. Patients receiving education may benefit from gaining a better understanding of their antineoplastic therapy. Understanding the side effects associated with the therapy may also help patients better be prepared to manage any adverse effects they may experience.

Full Title of Study: “Pharmacist-led Transitions of Care in the Outpatient Oncology Infusion Center”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Health Services Research
    • Masking: None (Open Label)
  • Study Primary Completion Date: June 30, 2021

Detailed Description

PRIMARY OBJECTIVE: I. To demonstrate the effectiveness of a clinical oncology pharmacist in the outpatient infusion center through education, and the identification and correction of medication related problem (MRP)s. SECONDARY OBJECTIVE: I. To evaluate overall patient and staff satisfaction with the added clinical oncology pharmacy education. EXPLORATORY OBJECTIVE: I. Estimate the cost avoidance utilizing the pharmacy services provided in the prospective trial. OUTLINE: PHASE I: Patients' medical records are reviewed. PHASE II: Patients receive pharmacist-led education on antineoplastic therapies including what to expect during infusion, general drug facts, common adverse effects, side effect management, and when to contact provider. After completion of study, patients are followed up periodically.

Interventions

  • Other: Medical Chart Review
    • Review of medical chart
  • Other: Educational Intervention
    • Receive pharmacist-led education
  • Other: Survey Administration
    • Ancillary studies

Arms, Groups and Cohorts

  • Experimental: Hearth services research (pharmacist-led education)
    • PHASE I: Patients’ medical records are reviewed. PHASE II: Patients receive pharmacist-led education on antineoplastic therapies including what to expect during infusion, general drug facts, common adverse effects, side effect management, and when to contact provider.

Clinical Trial Outcome Measures

Primary Measures

  • Number of medical related problem (MRP)s identified by the pharmacist through retrospective chart reviews (Phase I)
    • Time Frame: Up to 1 year
    • MRPs will be assigned to a specific category and the total number of MRPs in each category will be recorded. Categories include but are not limited to: incorrect dose, therapeutic duplication, drug not indicated, drug interaction, monitoring recommendation, drug allergy, or potential for adverse event.
  • Percent of MRPs corrected as a result of the clinical oncology pharmacist services (Phase II)
    • Time Frame: Up to 1 year
    • In phase 2 (prospective) MRPs will also be recorded and categorized, but in addition the outcomes relating to each MRP pharmacist intervention will be recorded. MRPs found by the pharmacist will be communicated to the patient’s oncologist or primary care provider, and the pharmacist will follow-up to see if changes were made.

Secondary Measures

  • Patient and provider satisfaction with the pharmacist-led education
    • Time Frame: Up to 1 year
    • The survey results will help determine the need for a clinical oncology pharmacist in the outpatient infusion center. Satisfaction will be assessed using a Likert-scale survey. Scale ranges from 1 (strongly disagree) to 5 (strongly agree).

Participating in This Clinical Trial

Inclusion Criteria

  • Solid tumor diagnosis – Starting day 1 of new antineoplastic infusion – English speaking (and/or English-speaking primary caregiver/proxy) Exclusion Criteria:

  • Metastasis to the brain and/or central nervous system (CNS) with evidence of impaired cognition – Severe cognitive impairment including dementia with inability to consent to the study

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 85 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Thomas Jefferson University
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Gloria Espinosa, PharmD, Principal Investigator, Sidney Kimmel Cancer Center at Thomas Jefferson University
  • Overall Contact(s)
    • Gloria Espinosa, PharmD, 215-955-9046, gloria.espinosa@jefferson.edu

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.